NeoGenomics (NEO) Tops Q4 EPS by 1c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/4/2026
- Wall Street ends lower as Middle East tensions escalate
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Broadcom's sales and AI chip forecast comes in below expectations, shares tumble
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Oil gains as Middle East hostilities flare
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Wall Street ends lower as Middle East tensions escalate
- After-Hours Stock Movers: AVGO, CRWD, FIVE, AI, TLYS, NTSK,
- After-Hours Stock Movers: PANW, CRWD, ZS, GTLB, ULTA
- After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP
- After-Hours Stock Movers: DELL, MDB, AEO, NTAP, GAP, S, ADSK
- After-Hours Stock Movers: CRM, MRVL, SNOW, HPQ, DDOG, MDB, P, SNPS, BRZE, NCNO
Neogenomics (NEO) PT Lowered to $17 at BTIG
February 19, 2025 2:57 PM ESTBTIG analyst Mark Massaro lowered the price target on Neogenomics (NASDAQ: NEO) to $17.00 (from $18.00) while maintaining a Buy rating.
The analyst comments "Shares of NEO have pulled back by ~30% following the (still surprising) news last month that the company's turnaround specialist and CEO, Chris Smith, will leave both the CEO seat and the... More
Neogenomics (NEO) PT Lowered to $17 at Morgan Stanley
February 19, 2025 8:05 AM ESTMorgan Stanley analyst Tejas Savant lowered the price target on Neogenomics (NASDAQ: NEO) to $17.00 (from $18.00) while maintaining a Equalweight rating.
The analyst comments "Surprising albeit small miss on pharma budget flush spoils long track record of beats/raises; 25 guide/LRP in line w/ Jan prelim;... More
Neogenomics (NEO) PT Lowered to $18 at Needham
February 18, 2025 4:01 PM ESTNeedham analyst Mike Matson lowered the price target on Neogenomics (NASDAQ: NEO) to $18.00 (from $19.00) while maintaining a Buy rating.
The analyst comments "NEO's 4Q24 revenue missed, while its EBITDA beat consensus. Management reiterated their 2025 revenue and EBITDA guidance. Revenue growth was... More
Raymond James Reiterates Market Perform Rating on Neogenomics (NEO)
February 18, 2025 8:12 AM ESTRaymond James analyst Andrew Cooper reiterated a Market Perform on Neogenomics (NASDAQ: NEO).
The analyst comments "Quick take: This morning NeoGenomics reported 4Q results with the top line roughly 70 bp below consensus and nearly 200 bp below our view. With Clinical Services and Advanced Diagnostics now combined into one segment, visibility is lessened, but we estimate the former roughly matched consensus while... More
